CLOVER HEALTH INVESTMENTS CO (CLOV) Stock Analyst Ratings
NASDAQ:CLOV • US18914F1030
2.02 USD
-0.07 (-3.35%)
At close: Feb 20, 2026
2.01 USD
-0.01 (-0.5%)
Pre-Market: 2/23/2026, 8:19:40 AM
ChartMill assigns a Buy % Consensus number of 76% to CLOV. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 2.92. This target is 44.54% above the current price.
- CLOV was analyzed by 10 analysts. The buy percentage consensus is at 76. So analysts seem to be have mildly positive about CLOV.
- In the previous month the buy percentage consensus was at a similar level.
- CLOV was analyzed by 10 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-01-20 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-11-06 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-08-07 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-08-06 | UBS | Maintains | Neutral -> Neutral |
| 2025-03-03 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-12-17 | Craig-Hallum | Initiate | Buy |
| 2024-10-07 | UBS | Initiate | Neutral |
| 2023-08-11 | Citigroup | Maintains | Neutral -> Neutral |
| 2023-03-06 | Canaccord Genuity | Maintains | Buy |
| 2023-03-06 | Credit Suisse | Maintains | Underperform |
| 2022-11-16 | Citigroup | Maintains | Neutral |
| 2022-11-08 | SVB Leerink | Maintains | Market Perform |
| 2022-08-09 | Credit Suisse | Maintains | Underperform |
| 2022-08-09 | Citigroup | Maintains | Neutral |
| 2022-05-10 | SVB Leerink | Maintains | Market Perform |
| 2022-02-25 | SVB Leerink | Maintains | Market Perform |
| 2022-02-02 | Cowen & Co. | Upgrade | Underperform -> Market Perform |
| 2022-02-02 | Canaccord Genuity | Initiate | Buy |
| 2022-01-19 | SVB Leerink | Initiate | Market Perform |
| 2022-01-07 | Credit Suisse | Downgrade | Neutral -> Underperform |
| 2021-11-15 | Credit Suisse | Maintains | Neutral |
| 2021-09-10 | Cowen & Co. | Initiate | Underperform |
| 2021-07-12 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2021-06-10 | B of A Securities | Downgrade | Neutral -> Underperform |
| 2021-05-19 | Credit Suisse | Maintains | Neutral |
| 2021-05-17 | B of A Securities | Downgrade | Buy -> Neutral |
| 2021-03-09 | Credit Suisse | Initiate | Neutral |
CLOVER HEALTH INVESTMENTS CO / CLOV FAQ
What is the average price target for CLOVER HEALTH INVESTMENTS CO (CLOV) stock?
10 analysts have analysed CLOV and the average price target is 2.92 USD. This implies a price increase of 44.54% is expected in the next year compared to the current price of 2.02.
Can you provide the consensus rating for CLOVER HEALTH INVESTMENTS CO stock?
The consensus rating for CLOVER HEALTH INVESTMENTS CO (CLOV) is 76 / 100 . This indicates that analysts generally have a positive outlook on the stock.
What is the number of analysts for CLOV stock?
The number of analysts covering CLOVER HEALTH INVESTMENTS CO (CLOV) is 10.